Xencor Inc Total Liabilities
Xencor Inc total liabilities. Based on the latest financial reports, Xencor Inc (XNCR) has total liabilities worth $243.50 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Xencor Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Xencor Inc (2011–2024)
Total liabilities of Xencor Inc from 2011 to 2024. This chart illustrates how Xencor Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Xencor Inc to see how much of total assets are deployed in long-term investments.
Xencor Inc Competitors by Total Liabilities
The table below lists competitors of Xencor Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xiamen International Airport Co Ltd
SHG:600897
|
China | CN¥859.64 Million |
|
Besalco Sa
SN:BESALCO
|
Chile | CL$1.05 Trillion |
|
Tyntek Corp
TW:2426
|
Taiwan | NT$972.75 Million |
|
Brainbees Solutions Limited
NSE:FIRSTCRY
|
India | Rs37.19 Billion |
|
Beijing CTJ Information Technology Co. Ltd.
SHE:301153
|
China | CN¥493.64 Million |
|
Gallant Micro Machining Co Ltd
TWO:6640
|
Taiwan | NT$3.45 Billion |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
China | CN¥940.80 Million |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥121.73 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Xencor Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Xencor Inc total assets.
Liquidity & Leverage Metrics
Xencor Inc Total Liabilities Ratios Explained
Xencor Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xencor Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xencor Inc (2011–2024)
The table below shows the annual total liabilities of Xencor Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $277.92 Million | -1.99% |
| 2023-12-31 | $283.56 Million | +138.75% |
| 2022-12-31 | $118.77 Million | +13.43% |
| 2021-12-31 | $104.71 Million | -19.95% |
| 2020-12-31 | $130.80 Million | +69.76% |
| 2019-12-31 | $77.05 Million | +39.96% |
| 2018-12-31 | $55.05 Million | -49.05% |
| 2017-12-31 | $108.06 Million | -5.72% |
| 2016-12-31 | $114.61 Million | +157.68% |
| 2015-12-31 | $44.48 Million | +421.25% |
| 2014-12-31 | $8.53 Million | -38.08% |
| 2013-12-31 | $13.78 Million | -55.77% |
| 2012-12-31 | $31.16 Million | -6.45% |
| 2011-12-31 | $33.31 Million | -- |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more